Earnings ·
REGENXBIO reports Q3 net loss of $0.62 per share, boosted by $38M Sarepta litigation settlement
RGNXREGENXBIO Inc.
REGENXBIO reported a third-quarter net loss of $40.7 million, or $0.62 per share, compared to a $61.9 million loss in the prior-year period. The improvement was driven by a $38.0 million gain from a patent litigation settlement with Sarepta Therapeutics and lower royalty expenses following the expiration of ZOLGENSMA patents in the U.S., which reduced revenue to $9.2 million from $29.7 million. Cash and equivalents stood at $251.0 million, supplemented by $39.0 million in settlement proceeds received in October. The company expects its current cash position will fund operations into late Q4 2027. REGENXBIO is a biotechnology company developing AAV gene therapies for rare neuromuscular and retinal diseases.